Literature DB >> 27009183

Battery longevity from cardiac resynchronization therapy defibrillators: differences between manufacturers and discrepancies with published product performance reports.

Mian Bilal Alam, Muhammad Bilal Munir, Rohit Rattan, Evan Adelstein, Sandeep Jain, Samir Saba.   

Abstract

AIMS: Cardiac resynchronization therapy (CRT) is an important treatment for heart failure that requires constant ventricular pacing, placing a high energy burden on CRT defibrillators (CRT-D). Longer battery life reduces the need for device changes and associated complications, thereby affecting patient outcomes and cost of care. We therefore investigated the time to battery depletion of CRT-D from different manufacturers and compared these results with manufacturers' published product performance reports (PPRs). METHODS AND
RESULTS: All CRT-D recipients at our institution between January 2008 and December 2010 were included in this study cohort. The patients were followed up to the endpoint of battery depletion and were otherwise censored at the time of death, last follow-up, or device removal for any reason other than battery depletion. A total of 621 patients [173 Boston Scientific (BSC), 391 Medtronic (MDT), and 57 St. Jude Medical (SJM)] were followed up for a median of 3.7 (IQR 1.6-5.0) years, during which time 253 (41%) devices were replaced for battery depletion. Compared with MDT devices, battery depletion was 85 and 54% less likely to happen with BSC and SJM devices, respectively (P < 0.001 for pairwise comparisons). Product performance reports from all manufacturers significantly overestimated battery longevity by more than 20% 6 years after device implantation.
CONCLUSIONS: Large differences in CRT-D battery longevity exist between manufacturers. Industry-published PPRs significantly overestimate device longevity. These data have important implications to patients, healthcare professionals, hospitals, and third-party payers. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2016. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  Battery longevity; Cardiac resynchronization therapy; Implantable cardioverter-defibrillator; Manufacturer; Product performance report

Mesh:

Year:  2017        PMID: 27009183     DOI: 10.1093/europace/euw044

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  8 in total

1.  "Real life" longevity of implantable cardioverter-defibrillator devices.

Authors:  Antonis S Manolis; Themistoklis Maounis; Spyridon Koulouris; Vassilios Vassilikos
Journal:  Clin Cardiol       Date:  2017-05-22       Impact factor: 2.882

2.  Device runtime and costs of cardiac resynchronization therapy pacemakers - a health claims data analysis.

Authors:  Moritz Hadwiger; Nikolaos Dagres; Gerhard Hindricks; Helmut L'hoest; Ursula Marschall; Alexander Katalinic; Fabian-Simon Frielitz
Journal:  Ger Med Sci       Date:  2022-03-04

Review 3.  ENDURALIFE-Powered Cardiac Resynchronisation Therapy Defibrillator Devices for Treating Heart Failure: A NICE Medical Technology Guidance.

Authors:  James Michael Evans; Andrew Cleves; Helen Morgan; Liesl Millar; Grace Carolan-Rees
Journal:  Appl Health Econ Health Policy       Date:  2018-04       Impact factor: 2.561

4.  The economic impact of battery longevity in implantable cardioverter-defibrillators for cardiac resynchronization therapy: the hospital and healthcare system perspectives.

Authors:  Maurizio Landolina; Giovanni Morani; Antonio Curnis; Antonello Vado; Antonio D'Onofrio; Valter Bianchi; Giuseppe Stabile; Martino Crosato; Barbara Petracci; Carlo Ceriotti; Luca Bontempi; Martina Morosato; Gian Paolo Ballari; Maurizio Gasparini
Journal:  Europace       Date:  2017-08-01       Impact factor: 5.214

5.  Longevity decoded: Insights from power consumption analyses into device construction and their clinical implications.

Authors:  Ernest W Lau
Journal:  Pacing Clin Electrophysiol       Date:  2019-03-05       Impact factor: 1.976

6.  Real-world evidence in health technology assessment of high-risk medical devices: Fit for purpose?

Authors:  Philip Klein; Hedwig Blommestein; Maiwenn Al; Benedetta Pongiglione; Aleksandra Torbica; Saskia de Groot
Journal:  Health Econ       Date:  2022-08-21       Impact factor: 2.395

7.  Economic impact of longer battery life of cardiac resynchronization therapy defibrillators in Sweden.

Authors:  Fredrik Gadler; Yao Ding; Nathalie Verin; Martin Bergius; Jeffrey D Miller; Gregory M Lenhart; Mason W Russell
Journal:  Clinicoecon Outcomes Res       Date:  2016-10-31

8.  Reliability and longevity of implantable defibrillators.

Authors:  Robert G Hauser; Susan A Casey; Christopher B Gitter; Chuen Y Tang; Raed H Abdelhadi; Charles C Gornick; Larissa Stanberry; Jay D Sengupta
Journal:  J Interv Card Electrophysiol       Date:  2021-01-02       Impact factor: 1.900

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.